For research and educational purposes only. Not medical advice.
Davunetide Reference
Educational, not medical advice reference for Davunetide: Cognitive; regulatory status, evidence posture, source review, and schedule notes. Also known as NA…
Reference summary
Davunetide has human clinical-trial history in neurodegenerative and neuropsychiatric contexts. The PSP Phase 2/3 trial failed primary endpoints, so community cognitive-enhancement claims should be tempered.
- Categories
- Cognitive
- Aliases
- NAP, AL-108, NAPVSIPQ, CP201
- Evidence posture
- human — Human trial history exists, but the major PSP program failed. Not an approved neuroprotective or nootropic product.
- Regulatory status
- No FDA-approved davunetide drug label. A Phase 2/3 progressive supranuclear palsy trial was completed and did not establish efficacy sufficient for approval.
- Content review status
- research reference